Home / Prices / Pharmacogenomic Testing Service Fee

Pharmacogenomic Testing Service Fee

Other estimated about CNY 300-900

Disclaimer: This site is a medical service platform; some page content is AI-assisted. Health-related information does not constitute medical advice. If you have any questions, please consult a healthcare professional. See full disclaimer

Description

A standardized billing charge for clinical interpretation and reporting of pharmacogenomic test results to guide medication selection and dosing in patient care.

Main Uses

Pharmacogenomic medication guidance service supports precision prescribing by identifying genetic variants affecting drug metabolism, transport, or targets. Primary uses include: optimizing drug selection (e.g., avoiding clopidogrel in CYP2C19 poor metabolizers); individualizing dosing (e.g., warfarin dosing guided by VKORC1/CYP2C9); predicting risk of adverse drug reactions (e.g., HLA-B*15:02-associated carbamazepine-induced SJS/TEN); informing therapeutic switching (e.g., SSRIs based on CYP2D6/CYP2C19 status); and supporting clinical decision-making in psychiatry, cardiology, oncology, and pain management per evidence-based guidelines (CPIC, FDA PGx biomarker labels).

Normal Range

Not applicable — Pharmacogenomic testing is qualitative or semi-quantitative; it does not yield numerical 'values' with a universal normal range. Instead, results are reported as genotype/allele calls (e.g., CYP2C19*1/*2), predicted phenotype (e.g., Poor Metabolizer, Normal Metabolizer), or clinical interpretation (e.g., 'Use alternative drug' or 'Reduce dose'). Reference standards depend on the specific gene-drug pair (e.g., CYP2C19 for clopidogrel; SLCO1B1 for simvastatin) and are defined by CPIC (Clinical Pharmacogenetics Implementation Consortium) or DPWG (Dutch Pharmacogenetics Working Group) guidelines.

Low Values - Possible Causes

N/A — 'Low value' is a misnomer for pharmacogenomic testing, as it does not measure analyte concentration. Apparent 'low' interpretations (e.g., reduced enzyme activity) stem from genetic variants: 1) Presence of loss-of-function alleles (e.g., CYP2C19*2 or *3); 2) Homozygous or compound heterozygous variant genotypes; 3) Gene deletions or copy number variants (e.g., CYP2D6 deletion); 4) Rare promoter variants reducing transcription; 5) Technical limitations (e.g., poor DNA quality or assay failure leading to inconclusive/missing calls).

High Values - Possible Causes

N/A — 'High value' is not applicable in standard pharmacogenomic reporting. Increased functional activity is inferred from genotypes: 1) Presence of gain-of-function alleles (e.g., CYP2D6*1xN or *2xN duplications); 2) Ultrarapid metabolizer genotype (e.g., CYP2D6 gene duplication + functional alleles); 3) Wild-type homozygous genotype (*1/*1) for genes where *1 denotes full function; 4) Absence of known loss-of-function variants; 5) Technical artifacts (e.g., allele dropout in one primer site causing false homozygous wild-type call).

pharmacogenomic testing personalized medicine clinical pharmacogenomics drug-gene interaction CPIC guidelines

estimated about CNY 300-900